Biocompatibility and proteomic profiling of DMSA-coated iron nanocubes in a human glioblastoma cell line.
Marina UlanovaLucy GloagChul-Kyu KimAndre BongersHong Thien Kim DuongJohn Justin GoodingRichard David TilleyPerminder Singh SachdevNady BraidyPublished in: Nanomedicine (London, England) (2024)
Background: Superparamagnetic iron core iron oxide shell nanocubes have previously shown superior performance in magnetic resonance imaging T2 contrast enhancement compared with spherical nanoparticles. Methods: Iron core iron oxide shell nanocubes were synthesized, stabilized with dimercaptosuccinic acid (DMSA-NC) and physicochemically characterized. MRI contrast enhancement and biocompatibility were assessed in vitro . Results: DMSA-NC showed a transverse relaxivity of 122.59 mM -1 ·s -1 Fe. Treatment with DMSA-NC did not induce cytotoxicity or oxidative stress in U-251 cells, and electron microscopy demonstrated DMSA-NC localization within endosomes and lysosomes in cells following internalization. Global proteomics revealed dysregulation of iron storage, transport, transcription and mRNA processing proteins. Conclusion: DMSA-NC is a promising T2 MRI contrast agent which, in this preliminary investigation, demonstrates favorable biocompatibility with an astrocyte cell model.
Keyphrases
- iron oxide
- contrast enhanced
- magnetic resonance imaging
- induced apoptosis
- oxidative stress
- magnetic resonance
- single cell
- iron deficiency
- cell cycle arrest
- computed tomography
- diffusion weighted imaging
- endothelial cells
- endoplasmic reticulum stress
- signaling pathway
- mass spectrometry
- dna damage
- cell death
- transcription factor
- stem cells
- cell therapy
- label free
- aqueous solution
- combination therapy